News for Healthier Living

Cleveland Clinic Research Finds Injectable Medications for Obesity Produce Smaller Weight Loss in A Real-World Setting, Compared to Randomized Clinical Trials

UNDER EMBARGO UNTIL Tuesday, June 10, 2025, 3 a.m. ET, CLEVELAND: A Cleveland Clinic study shows that semaglutide and tirzepatide - injectable GLP-1 drugs for obesity - produce smaller weight loss in a real-world setting because patients discontinue treatment or use lower maintenance dosages. Treatment discontinuation also negatively impacted blood sugar control in patients with prediabetes. The study was published in the Obesity Journal.

June 10, 2025


June 11 2025

June 10 2025

June 9 2025

June 8 2025

June 7 2025

June 6 2025

June 5 2025

June 4 2025

June 3 2025

June 2 2025

June 1 2025

May 31 2025

May 30 2025

May 29 2025

May 28 2025